Acceder

Publicaciones - ONCOLOGÍA CLÍNICA Y TRASLACIONAL

Cargando...
Encarnacion JA, Ibanez N, De la Fuente I, Ruiz P, Gonzalez S, Quiles B, Sanchez M, Bautista Y, Rodriguez C, Nadal JA, Marin M, Marin-Zafra G, Guirao M, Hernandez Q, Abrisqueta J, Abellan I, Montoya M, Ono A, Carbonell G, Frutos L, Ortiz E, Manso C, Royo-Villanova M, Alonso-Romero JL. Clinical Complete Response and Organ Preservation Strategies in Rectal Cancer: A Real-World Single-Center Experience Clinical Complete Response and Organ Preservation in Rectal Cancer. Cancers (Basel). 2026 Feb 27;18(5):763. doi: 10.3390/cancers18050763. PubMed PMID: 41827698; PubMed Central PMCID: PMC12985280.
AÑO: 2026; IF: 4.4
Almanchel-Rivadeneyra M, Alonso Romero JL, Tomas-Luiz A, Diaz Carrasco MS. Drug-drug interactions in adjuvant and neoadjuvant breast cancer therapy. Eur J Hosp Pharm. 2026 Jan 6:ejhpharm-2025-004761. doi: 10.1136/ejhpharm-2025-004761. Online ahead of print. PubMed PMID: 41494827.
AÑO: 2026; IF: 1.5
Mestre Terkemani Y, Rosado Jimenez L, Garcia Aliaga A, Sarabia Meseguer MD, Marin Vera M, Macias Cerrolaza JA, Sanchez Henarejos P, Garcia Hernandez MR, Zafra Poves M, Alvarez Abril B, Garcia Torralba E, Lopez Sanchez CB, Moya Martinez MP, Moreno Locubiche MA, Sanchez Martinez DA, Quiros Figello TA, Ceron Moreno AM, Exposito Garcia M, Anton Martinez D, Martinez Barba E, Ayala de la Pena F, Alonso Romero JL, Noguera Velasco JA, Ruiz Espejo F. Genetic testing for hereditary breast and ovarian cancer in the Murcian population using a comprehensive NGS panel. Fam Cancer. 2026 Mar 23;25(2):31. doi: 10.1007/s10689-026-00544-5. PubMed PMID: 41870673.
AÑO: 2026; IF: 2.0
Agrawal Y.N., Fernández-Martnez A., Gil-Gil M., Zielinski C., Ruiz-Borrego M., Ciruelos E.M., Muñoz M., Margel M., Bermejo B., Antón A., Kahan Z., Csöszi T., Alonso-Romero J.L., Garca-Saenz J.Á., Sánchez-Rovira P., Álvarez E., Chacón J.I., González-Santiago S., Rodrguez C.A., Servitja S., Pfefferle A.D., Herranz J., Liu Y., Carey L.A., Romero-Camarero I., Caballero R., Guerrero-Zotano Á., Perou C.M., Martn M. Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial. JCO Precision Oncology. 1 July 2025. 9. 10.1200/PO-24-00937
AÑO: 2025; IF: 5.6
Marquez-Rodas I, Dutriaux C, Saiag P, de la Cruz Merino L, Castanon Alvarez E, Robert C, Rodriguez-Moreno JF, Arance A, Cerezuela-Fuentes P, Montaudie H, Sanmamed MF, Gonzalez-Cao M, Charles J, Lopez Criado MP, Berrocal A, de Miguel E, Funck-Brentano E, Prey S, Alamo de la Gala MC, Melero I, Aviles-Izquierdo JA, Roman R, Garcia-Pelaez B, Rodriguez S, Trnkova ZJ, Quintero M, Macia S, Chaney MF, Dalle S. BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. J Clin Oncol. 2025 Jun 27:JCO2402595. doi: 10.1200/JCO-24-02595. Online ahead of print. PubMed PMID: 40577656.
AÑO: 2025; IF: 41.9
< AnteriorSiguiente >

Instituto de Investigación Sanitaria Acreditado

ISCII